Overview A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Status: Recruiting Trial end date: 2026-07-31 Target enrollment: Participant gender: Summary A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia. Phase: Phase 1 Details Lead Sponsor: Biomea Fusion Inc.